mCureX Therapeutics, a subsidiary of a leading RNAi therapeutics company OliX Pharmaceuticals, focuses on the research and development of mRNA (messenger RNA) vaccines and therapeutics. We have in-house competencies spanning proprietary technology, preclinical and clinical development to commercialization, as well as production know-how to design mRNA molecular structures. Utilizing modified nucleotide technology that has secured FTO (Freedom to Operate), we have completed the selection of lead candidates for COVID-19 vaccines and initiated production. Based on our proprietary mRNA platform, we aim to be the first mover in the mRNA therapeutics and vaccines market. We plan to expand our pipeline into various indications, including infectious diseases such as influenza, cancer, respiratory, and liver diseases. Please look forward to the history that mCureX, your messenger for cure, will make.
Location: South Korea, Kyeongki-Do, Seongnam-si
Employees: 11-50
Founded date: 2021